Hubungan Kategori Level Xpert MTB/RIF dengan Waktu Konversi Kultur Sputum Pasien TB Resisten Obat (TB RO)
DOI:
https://doi.org/10.55175/cdk.v47i9.565Kata Kunci:
TB RO, waktu konversi kultur sputum, Xpert MTB/RIFAbstrak
Penanganan TB yang tidak tepat dan tidak sesuai standar dapat menimbulkan masalah TB resisten obat (TB RO). Penelitian ini bertujuan mengetahui hubungan antara kategori level hasil Xpert MTB/RIF dan waktu konversi kultur sputum pasien TB RO. Data berasal dari rekam medik mulai bulan September 2012 sampai dengan bulan Oktober 2015; didapatkan 198 pasien TB RO, 112 laki-laki (56,6%) dan 86 perempuan (43,4%). Usia rerata 38,87 ± 12,41 tahun. Seluruh pasien TB RO merupakan pasien TB paru dengan memiliki riwayat pengobatan OAT kategori 1. Hasil pemeriksaan Xpert MTB/RIF menunjukkan sebagian besar pasien TB RO berada pada kategori low (43,9%). Konversi kultur terbanyak pada minggu ke-4 sampai ke-8 pengobatan sebesar 59,1%. Tidak ada perbedaan bermakna antara kategori Xpert MTB/RIF dan waktu konversi kultur sputum pasien TB RO (CI 95%, p = 0,572). Tidak ada korelasi bermakna antara kategori level gene X-pert dan waktu konversi kultur sputum pasien TB RO (CI 95%, r = 0,061; p = 0,392).
nadequate TB management can cause the emergence of drug resistant tuberculosis. This study is to determine the correlation between Xpert MTB/RIF levels category with sputum culture conversion time in drug resistant tuberculosis patients. This retrospective cohort study was conducted in PMDT clinic at Dr. Moewardi General Public Hospital, Surakarta from September 2012 until October 2015. The respondents were 198 drug resistant tuberculosis patients; 112 males (56.6%) and 86 females (43.4%), mean age 38.87 ± 12.41 years old. All were pulmonary TB patients with category 1 anti-TB treatment. The Xpert MTB/RIF levels were mostly low category (43.9%). Culture conversion showed that 59.1% had conversion between the fourth and eighth week of drug resistant tuberculosis treatment. No statistically significant difference between Xpert MTB/FIR level category and sputum culture conversion time (CI 95%, p = 0.572). No statistically significant correlation between Xpert MTB/RIF level category and sputum culture conversion time (CI 95%, r = 0.061; p = 0.392)
Unduhan
Referensi
World Health Organization (WHO).Global tuberculosis report, 2015. Geneva (Switzerland): WHO Library Cataloguing-in-Publication Data; 2015.
World Health Organization (WHO). Global tuberculosis report, 2016. Geneva (Switzerland): WHO Library Cataloguing-in-Publication Data; 2016.
World Health Organization (WHO). Tuberculosis control in the south-eastasia region: annual report 2015. New Delhi (India): WHO Library Cataloguing-in-Publication Data; 2015.
Kementerian Kesehatan RI. Riset kesehatan dasar (riskesdas) 2013. Jakarta (Indonesia): Badan Penelitian Dan Pengembangan Kesehatan Kementerian Kesehatan RI; 2013.
Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis : predictors and relationship to treatment outcome. Ann Intern Med. 2006; 144(9):650-9.
Garcell HG, Castaneda MM, Artiles MA, Garcia FG, Basulto MAP, Alejo AP, et al. Factors related with sputum smear conversion time among tuberculosis patients. Walailak J Sci Tech. 2016; 13(4):251-60.
Zeka AN, Tasbakan S, Cavusoglu C. Evaluation of the gene xpert MTB / RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extra pulmonary specimens. J Clin Microbiol. 2011; 49(12):4138-41.
Blakemore R, Story E, Helb D, Kop JA, Banada P, Owens MR, et al. Evaluation of the analytical performance of the xpert MTB / RIF assay. J Clin Microbiol. 2010; 48(7):2495-501.
van Zyl-smit RN, Binder A, Meldau R, Mishra H, Semple PL, Theron G, et al. Comparison of quantitative techniques including xpert MTB / RIF to evaluate mycobacterial burden. PLoS One. 2011; 6(12):1-10.
Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, et al. A multisite assessment of the quantitative capabilities of the xpert MTB / RIF assay. Am J Respir Crit Care Med. 2011; 184(7):1076-84
Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of xpert MTB / RIF and genotype MTBDR plus for patient selection for a tuberculosis clinical trial. J Clin Microbiol. 2011; 49(8):2827-31.
Theron G, Pinto L, Peter J, Mishra HK, Mishra HK, van Zyl-Smit R, et al. The use of an automated quantitative polymerase chain reaction ( xpert mycobacterium tuberculosis / RIF ) to predict the sputum smear status of tuberculosis patients. Clinical Infectious Disease. 2011;12:1-5.
Patel VB, Theron G, Lenders L, Matinyena B, Connoly C, Singh R, et al. Diagnostic accuracy of quantitative PCR ( xpert MTB / RIF ) for tuberculous meningitis in a high burden setting : aprospective study. PLoS One. 2013; 10(10):1-13.
Theron G, Peter J, Calligaro G, Meldau R, Hanrahan C, Khalfey H, et al. Determinants of PCR performance (xpert MTB/RIF), including bacterial load and inhibition, for tb diagnosis using specimens from different body compartments. Scientific Reports. 2014;4:565-75.
Basit A, Ahmad N, Khan AH, Javaid A, Sulaiman SAS, Afridi AK, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis : findings from a retrospective cohort study. PLoS One. 2014; 9(4):1-6.
Rodriguez M, Monedero I, Caminero JA, Encarnation M, Dominguez Y, Acosta I, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominicanrepublic. Int J Tuberc Lung Dis. 2013; 17(4):520-5.
Olaru ID, Heyckendorf J, Grossmann S, Lange C. Time to culture positivity and sputum smear microscopy during tuberculosis therapy. PLoS One.2014; 9(8):1-6.
Shenai S, Ronacher K, Malherbe S, Stanley K, Kriel M, Winter J, et al. Bacterial loads measured by the xpert MTB / RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB. PLoS One. 2016; 11(8):1-13.
Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, et al. Assessment of the sensitivity and specificity of xpert MTB / RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2013; 1(6):462-70.
Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis : systematic review and meta-analysis. Lancet Infect Dis. 2009; 9(3):153-61
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2020 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
